Masimo Corporation · NASDAQ:MASI
Masimo — Q2 2018 Earnings Presentation
12 slides from Masimo's earnings presentation, Aug 1, 2018
Slide 1: Q2 2018 Results Supplemental Presentation to Earnings Press Release
Q2 2018 Results Supplemental Presentation to Earnings Press Release August 1, 2018 © 2018 Masimo. All Rights Reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements All statements other than statements of historical facts contained herein that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP). The non-GAAP financial measures presented exclude the items that are more fully desc
Slide 4: Impact of Adoption of New Accounting Standard (ASC 606)
Impact of Adoption of New Accounting Standard (ASC 606) During the first quarter of 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update No. 2014-09, Revenue (Topic 606): Revenue from Contracts with Customers (ASU 2014-09). The new revenue recognition sta
Slide 5: Masimo Today
Masimo Today ~$822M >100 Million annual product patients revenue 1 impacted each year 2 >140 countries Innovator Leader in noninvasive in pulse patient oximetry monitoring Primary pulse oximetry technology at 17 of the top 20 hospitals listed in the 2017-2018 U.S. News & technologies World Report Be
Slide 6: Seven Year Plan
Seven Year Plan ► Our customers and partners are embracing us ► Targeting long-term revenue growth of 8%-10% ► Targeting long-term operating profit margin of 30% ► Targets do not include contributions from products in pipeline or M&A ► We are a 29 year-old company that has the passion of a start-up
Slide 7: Q2 2018 Highlights
Q2 2018 Highlights ► Total revenue, including royalty and other revenue, of $211.6 million ► Product revenue increased 12.4% to $202.0 million, up 11.2% on a constant currency basis ► GAAP operating profit margin of 24.4%; Non-GAAP operating profit margin increased 160 basis points to 24.6% ► GAAP d
Slide 8: Q2 2018 Financial Performance
Q2 2018 Financial Performance GAAP Non-GAAP Measures 1 $ in millions, except EPS Q2 2018 Q2 2018 vs. Prior Year YoY Performance Highlights Total revenue grew 10.0% due to strong product revenue growth of 12.4% offset by a reduction of Total Revenue $211.6M $211.6M 10.0% ~$2.8M in non-recurring engin
Slide 9: 2018 Full-Year Financial Guidance
2018 Full-Year Financial Guidance 1 GAAP Non-GAAP Measures 2 $ in millions, except EPS FY 2018 FY 2018 vs. Prior Year YoY Performance Highlights Total Revenue $850M $850M 7.5% Total revenue includes royalty and other revenue of ~$28 million. Product revenue growth of ~11.3% reported and ~10.8% exclu
Slide 10: Driving Shareholder Value Through Growth and Profitability
Driving Shareholder Value Through Growth and Profitability Product Revenue 2 Adjusted EBITDA 2 Non-GAAP EPS 2 (in Millions) (in Millions) ($ per share) 1 1 1 1 Masimo 2018 financial guidance as of August 1, 2018 2 Please refer to our Non-GAAP financial measures and definitions as previously describe
Slide 11: Investment Highlights
Investment Highlights Improve Patient Care and Reduce Cost of Care through Innovation-Ultimate Way to Drive Shareholder Value #3 #1 #2 #4 #5 Tax Rate Grow Revenues Expand Margins EPS Growth Free Cash Flow Improvement Grow revenues at Target long-term Optimizing tax structure Targeting double digit E
Slide 12: © 2018 Masimo. All Rights Reserved.
© 2018 Masimo. All Rights Reserved.